Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.…
National Advertising Division Will Refer Beyond Air to Regulatory Authorities for Declining to Participate in Self-Regulatory Process
Beyond Air (NASDAQ: XAIR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 54 employees.
The shares were at 1.540 USD on 20 November 2026, down 95.5% over 52 weeks. Its 52-week range is 1.530 USD to 53.20 USD, and it trades at the bottom of that range.
Its market capitalisation is 2.57M USD.
Beyond Air reports an operating margin of -321.7% and revenue up 27.8% year over year.
Its debt exceeds its cash by 12.10M USD, a debt-to-equity ratio of 3.82. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 11 February 2027.